Literature DB >> 7617539

Nicotine dependence, midbrain dopamine systems and psychiatric disorders.

M Nisell1, G G Nomikos, T H Svensson.   

Abstract

Compelling evidence exists that tobacco-smoking represents a form of drug addiction to nicotine. Like several drugs of abuse, nicotine activates the mesolimbic dopamine system and this effect appears to be of critical importance for the reinforcing properties of the drug. Specifically, nicotine has been shown to increase burst activity in dopamine neurones of the ventral tegmental area, i.e. a mode of firing pattern in these cells which is physiologically associated with basic motivational processes underlying learning and cognitive behaviour. The stimulatory action of nicotine on mesolimbic dopamine neurones is exerted both at the somatodendritic and at the terminal levels. Yet, the release of dopamine in the nucleus accumbens induced by systemically administered nicotine is abolished by the nicotine receptor antagonist, mecamylamine when administered locally in the ventral tegmental area, but not in the nucleus accumbens. Whereas continuous infusion of nicotine into the ventral tegmental area produces a long-lasting increase in accumbal dopamine release, analogously to the effect of systemically administered nicotine, continuous infusion of nicotine into the nucleus accumbens produces a very short-lasting dopamine release. Thus, nicotinic receptors in the ventral tegmental area appear to be more significant than those located in the nucleus accumbens for mediating the stimulatory effect of nicotine on dopamine release in the nucleus accumbens. The effect of nicotine on midbrain dopamine systems may help to explain the extremely high prevalence of tobacco-smoking in schizophrenics, who frequently display so-called hypofrontality, i.e. a reduced functional activity in the prefrontal cortex which provides a direct input to the ventral tegmental area dopamine cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617539     DOI: 10.1111/j.1600-0773.1995.tb00123.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  27 in total

Review 1.  Biological mechanisms underlying the relationship between stress and smoking: state of the science and directions for future work.

Authors:  Jessica M Richards; Brooke A Stipelman; Marina A Bornovalova; Stacey B Daughters; Rajita Sinha; C W Lejuez
Journal:  Biol Psychol       Date:  2011-07-07       Impact factor: 3.251

Review 2.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

3.  Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons.

Authors:  L Azam; Y Chen; F M Leslie
Journal:  Neuroscience       Date:  2006-12-29       Impact factor: 3.590

Review 4.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 5.  Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?

Authors:  Judith J Prochaska; Sharon M Hall; Lisa A Bero
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

Review 6.  Heterogeneity of reward mechanisms.

Authors:  A Lajtha; H Sershen
Journal:  Neurochem Res       Date:  2009-12-12       Impact factor: 3.996

7.  Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Authors:  M L Gregório; E C Wietzikoski; M M Ferro; J L M Silveira; M A B F Vital; C Da Cunha
Journal:  Neurotox Res       Date:  2009-03-18       Impact factor: 3.911

8.  Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia.

Authors:  Steven L Batki; Luba Leontieva; Jacqueline A Dimmock; Robert Ploutz-Snyder
Journal:  Schizophr Res       Date:  2008-08-13       Impact factor: 4.939

Review 9.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

10.  Amphetamine administration into the ventral striatum facilitates behavioral interaction with unconditioned visual signals in rats.

Authors:  Rick Shin; Junran Cao; Sierra M Webb; Satoshi Ikemoto
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.